FDA Inspection 1167416 — Bloodworks
The FDA completed an inspection of Bloodworks on March 15, 2022 in Seattle, WA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 15, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Seattle, WA (United States)